Brief: Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan
22/08/2019 18:04
Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T :
* CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR
ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
FROM JAPAN'S MHLW
* CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE
I/III
IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY
ENDPOINT OF OVERALL SURVIVAL
Source text (https://bit.ly/2zhtTDX)
Further company coverage: 4519.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)